C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy
The purpose of this study is to evaluate the efficacy and safety of the study drug, MLN0128 in combination with fulvestrant, in patients with advanced or metastatic Breast Cancer that has progressed during or after aromatase inhibitor therapy.
Advanced/Metastatic Breast Cancer
≥ 18 years of age
ER-positive/HER-2-negative Advanced or Metastatic Breast Cancer
Previously treated with aromatase inhibitor therapy and progressed
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.
OHSU Knight Cancer Institute Information line 503-494-1080
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited